Michigan State University/Breslin Cancer Center — Lansing, Michigan

Michigan State University/Breslin Cancer Center is a clinical research site located in Lansing, Michigan, United States 48910.

Crixeo Clinical Trials Trust Score: 92/100 (GOOD). This profile has not yet been claimed by the site owner.

Michigan State University/Breslin Cancer Center has participated in 19 clinical trials with 2 currently active.

Therapeutic areas: Multiple Myeloma, Breast Cancer, Acute Leukemias of Ambiguous Lineage.

Sponsors: Celgene, NSABP Foundation Inc, Children's Oncology Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Lansing

Browse all research sites in Michigan · View every site in Lansing

Sponsor Feasibility Report

Trust Score: 92/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Michigan State University/Breslin Cancer Center?

Michigan State University/Breslin Cancer Center has a Crixeo Trust Score of 92/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Michigan State University/Breslin Cancer Center conducted?

Michigan State University/Breslin Cancer Center has 19 clinical trials on record, with 2 currently active. Their work covers Multiple Myeloma, Breast Cancer, Acute Leukemias of Ambiguous Lineage.

Is Michigan State University/Breslin Cancer Center accredited by Crixeo Clinical Trials?

Michigan State University/Breslin Cancer Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Michigan State University/Breslin Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.